Contraindications and DDIs

INDICATION

DESCOVY® for HIV-1 pre-exposure prophylaxis (PrEP) is indicated in at-risk adults and adolescents (≥35 kg) to reduce the risk of sexually acquired HIV-1 infection, excluding individuals at risk from receptive vaginal sex. HIV-1–negative status must be confirmed immediately prior to initiation.

Limitation of Use: DESCOVY FOR PrEP is not indicated in individuals at risk of HIV-1 from receptive vaginal sex because effectiveness in this population has not been evaluated.

Contraindications and drug interactions1

Contraindication

  • DESCOVY FOR PREP™ is contraindicated in patients with unknown or positive HIV status

Drug interactions

  • Prescribing information: Consult the full Prescribing Information for DESCOVY® for more information, warnings, and potentially significant drug interactions, including clinical comments
  • Metabolism: Drugs that inhibit P-gp can increase the concentrations of tenofovir alafenamide (TAF), a component of DESCOVY. Drugs that induce P-gp can decrease the concentrations of TAF, which may lead to loss of efficacy
  • Drugs affecting renal function: Coadministration of DESCOVY with drugs that reduce renal function or compete for active tubular secretion may increase concentrations of FTC and tenofovir and the risk of adverse reactions

Please see full Prescribing Information for DESCOVY FOR PrEP, including BOXED WARNING.

DDl=drug-drug interaction.